<DOC>
	<DOCNO>NCT00068081</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability NGX 4010 apply 60 minute treatment PHN .</brief_summary>
	<brief_title>Controlled Study NGX-4010 Treatment Postherpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>At least 18 year age . Be good health . Diagnosis postherpetic neuralgia ( PHN ) make primary treating physician Investigator , least 3 month postvesicle crust . Screening Pain Sum Score 12 36 . Intact , unbroken skin painful area ( ) treat . If take chronic pain medication , stable ( PRN ) regimen least 21 day prior Treatment Visit ( Day 0 ) willing maintain medication stable dose ( ) schedule throughout study . Female subject childbearing potential must negative serum beta hCG pregnancy test , perform Screening Visit . All subject must willing use effective method birth control and/or refrain participate conception process study 30 day follow experimental drug exposure . Be willing able comply protocol requirement duration study participation . ( Such requirement include , limited : complete daily pain diary , attend study visit , refrain elective surgery extensive travel study participation . ) Concomitant opioid medication , unless orally transdermally administer exceed total daily dose morphine 60 mg/day , equivalent . Parenteral opioid use exclude , regardless dose . Unavailability effective rescue medication strategy subject , unwillingness use opioid analgesic treatment , high tolerance opioids preclude ability relieve treatmentassociated discomfort Roxicodone® , judge Investigator . Active substance abuse history chronic substance abuse within past year , prior chronic substance abuse judge likely recur study period investigator . Recent use ( within 21 day precede Treatment Visit [ Day 0 ] ) topically apply pain medication , nonsteroidal antiinflammatory drug , menthol , methyl salicylate , local anesthetic ( include Lidoderm® ) , steroid capsaicin product painful area . Current use investigational agent , Class 1 antiarrhythmic drug ( tocainide mexiletine ) . Significant pain etiology PHN , example , compressionrelated neuropathy ( e.g. , spinal stenosis ) fibromyalgia arthritis . Subjects must significant ongoing pain cause ( ) may interfere judge PHNrelated pain . Painful PHN area locate face , hairline scalp , and/or proximity mucous membrane . ( Investigational treatment NGX4010 allow area . ) Any implanted medical device ( spinal cord stimulator , intrathecal pump peripheral nerve stimulator ) treatment neuropathic pain . Hypersensitivity capsaicin ( i.e. , chili pepper OvertheCounter ( OTC ) capsaicin product ) , local anesthetic , Roxicodone® adhesives . Significant ongoing untreated abnormality cardiac , renal , hepatic , pulmonary function may interfere either ability complete study evaluation adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Dermal assessment</keyword>
	<keyword>Pain measurement</keyword>
	<keyword>Diary</keyword>
	<keyword>Analgesics/*therapeutic use</keyword>
	<keyword>Capsaicin/*administration &amp; dosage/adverse effect</keyword>
	<keyword>Herpes zoster/*complication/drug therapy</keyword>
	<keyword>Neuralgia/*drug therapy/etiology</keyword>
	<keyword>Pain</keyword>
	<keyword>Peripheral nervous system diseases/*complications</keyword>
</DOC>